Welcome to our dedicated page for TransDigm Group SEC filings (Ticker: TDG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TransDigm Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TransDigm Group's regulatory disclosures and financial reporting.
TransDigm Group director Robert J. Small reported sales of the company’s common stock in a Form 4 filing. On 12/09/2025, entities associated with him sold 75,673 and 15,280 shares of TransDigm common stock at $1,335.72 per share.
After these transactions, 366,141 shares are held indirectly through Stockbridge Fund, L.P., 68,139 shares through Stockbridge Partners LLC, and 60,246 shares through certain family trusts, with an additional 5,625 shares held directly. The filing states that Small may be deemed to share voting and dispositive power over these holdings but disclaims beneficial ownership beyond any pecuniary interest.
A shareholder of TDG has given notice of intent to sell 100,000 shares of common stock through Goldman, Sachs & Co., with an aggregate market value of $134,717,000. The notice states that there are 56,318,584 shares of this common stock outstanding and that the proposed sale is to be made on the NYSE on or about 12/09/2025.
In addition, the disclosure shows that Stockbridge Partners LLC sold 5,000 shares of the same common stock in the past three months, on 09/12/2025, for gross proceeds of $6,384,923.50. The seller represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
TransDigm Group Inc. reported an insider stock transaction involving a company director. A stock option for 17,526 shares of common stock with an exercise price of $105.88 was exercised on 12/04/2025 and held indirectly through the Fortuna Trust dated June 1, 2018.
The trust then reported a series of open-market sales of TransDigm common stock on the same date at weighted average prices ranging from about $1,360.0000 to $1,367.2300 per share. After these transactions, the trust held 8,158 shares of TransDigm common stock and 37,940 derivative securities beneficially owned. The filing notes that the reported sale prices are weighted averages and that full price breakdowns for each trade within the ranges are available upon request.
A shareholder has filed a notice of proposed sale of 17,526 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $23,438,045.58, compared with 56,318,584 shares of the same class reported as outstanding. The seller acquired these 17,526 shares on 12/04/2025 through a cash exercise of stock options on that date.
Over the past three months, the person for whose account the securities are to be sold, identified in multiple entries as The Fortuna Trust U/T/A DTD 06/01/2018, has already sold several blocks of common stock under a Rule 10b5-1 plan, including 7,191 shares on 11/18/2025 for $9,791,047.47 and 4,592 shares on 11/28/2025 for $6,248,486.61. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
TransDigm Group Inc. insider transaction: A company officer serving as Co‑Chief Operating Officer reported an option exercise and related stock sale. On 12/01/2025, the insider exercised a stock option to acquire 290 shares of TransDigm common stock at an exercise price of $269.42 per share, then on the same date sold 290 shares of common stock at a price of $1,351.06 per share.
After these transactions, the insider directly beneficially owned 1,055 shares of TransDigm common stock and 1,740 stock options. The filing was made as a Form 4 by one reporting person, reflecting routine insider equity activity.
TDG received a Form 144 notice indicating a planned sale of common stock under Rule 144. A holder intends to sell 290 common shares through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $394,449.30. The issuer had 56,318,584 common shares outstanding at the time referenced.
The 290 shares to be sold were acquired on 12/01/2025 by exercising stock options from the issuer, paid in cash on the same date. Over the prior three months, 10b5-1 sales for Patrick J. Murphy included 290 common shares on 11/03/2025 for $379,900.00 and 580 common shares on 10/27/2025 for $785,760.80.
TransDigm Group Inc. filed a Form 4 reporting equity transactions by director Kevin Stein through the Fortuna Trust dated June 1, 2018. On 11/28/2025, the trust exercised a stock option for 4,592 shares of TransDigm common stock at an exercise price of $105.88 per share. The option relates to an award originally exercisable from 09/30/2018 and expiring on 04/25/2028, and its exercise price has been adjusted for dividends declared since August 1, 2022.
On the same date, the trust reported sales of TransDigm common stock in three transactions of 2,997, 1,545 and 50 shares at volume-weighted average prices of approximately $1,360.44, $1,361.25 and $1,362.43, respectively, within narrow intraday price ranges. Following these transactions, the Fortuna Trust indirectly held 8,158 shares of TransDigm common stock.
A shareholder affiliated with NYSE: TDG has filed a Form 144 notice covering the planned sale of 4,592 shares of common stock. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of 6,222,205.92 reported in the notice, compared with 56,318,584 shares outstanding. The seller acquired these 4,592 shares on the same date via a cash exercise of stock options.
The filing also lists a series of prior Rule 10b5-1 plan sales over the past three months by The Fortuna Trust, each disclosing the number of common shares sold and the gross proceeds on specific dates in October and November 2025. The signer represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
TransDigm Group Inc. (TDG) director Kevin Stein, through the Fortuna Trust dated June 1, 2018, reported stock option exercises and related share sales. On 11/25/2025, the trust exercised 4,187 stock options at an exercise price of $105.88 per share and then sold 4,097 common shares at a weighted average price of $1,360.5495 per share, plus an additional 90 shares at a weighted average price of $1,361.8702 per share. On 11/26/2025, the trust exercised another 30 stock options at $105.88 per share and sold 30 shares at $1,360.06 per share. After these transactions, the trust beneficially owned 8,158 TDG common shares and 60,058 stock options indirectly.
A selling stockholder of TransDigm Group Inc. (TDG) filed a Form 144 notice to sell 4,187 common shares through Morgan Stanley Smith Barney LLC on the NYSE. The shares have an indicated aggregate market value of $5,592,827.12, while 56,318,584 common shares were shown as outstanding; this is a baseline figure, not the amount being sold. The shares to be sold were acquired on 11/25/2025 by exercising stock options for cash on the same date.
The notice also lists prior Rule 10b5-1 plan sales over the past three months for The Fortuna Trust U/T/A DTD 06/01/2018, including 7,191 shares sold on 10/18/2025 for gross proceeds of $9,791,047.47 and 1,104 shares sold on 11/20/2025 for $1,502,423.47. By signing, the seller represents they are not aware of undisclosed material adverse information about TransDigm’s operations.